{"filing":{"accession_number":"0001193125-26-338020","cik":"0000876343","ticker":"LCTX","company_name":"Lineage Cell Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"lctx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/lctx-20260806.htm"},"events":[{"id":25629,"run_id":23260,"accession_number":"0001193125-26-338020","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The Item 2.02 disclosure explicitly states that Lineage \"issued a press release announcing financial results for the quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenues ($1.1M), operating expenses ($10.0M), operating loss ($8.9M), and net income ($1.5M), along with balance sheet highlights and comprehensive business updates on clinical programs and pipeline progress.","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26513,"accession_number":"0001193125-26-338020","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The Item 2.02 disclosure explicitly states that Lineage \"issued a press release announcing financial results for the quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenues ($1.1M), operating expenses ($10.0M), operating loss ($8.9M), and net income ($1.5M), along with balance sheet highlights and comprehensive business updates on clinical programs and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:31.844718+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26513,"accession_number":"0001193125-26-338020","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The Item 2.02 disclosure explicitly states that Lineage \"issued a press release announcing financial results for the quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenues ($1.1M), operating expenses ($10.0M), operating loss ($8.9M), and net income ($1.5M), along with balance sheet highlights and comprehensive business updates on clinical programs and pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:18:31.844718+00:00","company_name":"Lineage Cell Therapeutics, Inc.","ticker":"LCTX","filing_date":"2026-08-06"}]}